Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 378
S. Maude, T. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. Verneris, H. Stefanski, G. Myers, M. Qayed, B. Moerloose, H. Hiramatsu, Krysta Schlis, K. Davis, P. Martin, Eneida Nemecek, G. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. June, B. Levine, P. Wood, T. Taran, M. Leung, K. Mueller, Yiyun Zhang, K. Sen, D. Lebwohl, M. Pulsipher, S. Grupp (2018)
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic LeukemiaThe New England Journal of Medicine, 378
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, C. Cowey, C. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. Ferrucci, A. Hill, J. Wagstaff, M. Carlino, J. Haanen, M. Maio, I. Márquez-Rodas, G. McArthur, P. Ascierto, G. Long, M. Callahan, M. Postow, M. Postow, K. Grossmann, M. Sznol, B. Dréno, L. Bastholt, A. Yang, L. Rollin, C. Horak, F. Hodi, J. Wolchok, J. Wolchok (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.The New England journal of medicine, 373 1
Jun Tang, A. Shalabi, Vanessa Hubbard-Lucey (2018)
Comprehensive analysis of the clinical immuno-oncology landscapeAnnals of Oncology, 29
editorial memo (2018) 11:82–83 https://doi.org/10.1007/s12254-018-0412-2 The adolescence of cancer immunotherapy: from a difficult childhood to a pillar of modern anticancer therapy Thorsten Fuereder Received: 4 May 2018 / Accepted: 9 May 2018 / Published online: 24 May 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Cancer immunotherapy was born in the 1890s and became standard of care and the preferred treatment raised by its father William Coley, who provoked an option in a variety of malignancies: in metastatic immune response by injecting a mixture of different melanoma, which is regarded as almost unrespon- bacteria into patients suffering from a variety of sarco- sive to dacarbazine chemotherapy, the Checkmate mas. Although impressive responses were observed, 066 and 067 trials set a new gold standard for this the efficacy of Coley’s toxin was unpredictable and disease with a 3-year overall survival (OS) rate of 58% lethal side effects occurred. Therefore, immunother- in the ipilimumab/nivolumab combination arm [2]. apy was shelved for several decades and alternative Likewise, in metastatic non-small cell lung cancer concepts such as radiation or chemotherapy were (NSCLC) long-term survival can be achieved by im- preferred. With the advent of molecular oncology, munotherapy. Very recently, the Keynote
memo - Magazine of European Medical Oncology – Springer Journals
Published: May 24, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.